Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NOVONIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NOVONIX's regulatory disclosures and financial reporting.
NOVONIX Limited reported quarterly operational and cash flow details while progressing its strategic graphite anode active material business. The company delivered a mass-production C-sample of synthetic graphite AAM to Panasonic Energy, with internal testing indicating it meets specifications, and reaffirmed its target to begin mass production for Panasonic in the second half of 2027, subject to completion of qualification. It completed an institutional placement of A$20.7 million and raised A$0.96 million via a share purchase plan, and the U.S. Government certified the Riverside project in connection with a previously allocated US$103 million Section 48C tax credit. NOVONIX also closed the divestiture of its Battery Technology Solutions division.
For the quarter ended 30 June 2026, net cash used in operating activities was 8,642 $USD’000 and investing outflows were 2,441 $USD’000, while financing activities provided 13,226 $USD’000. Cash and cash equivalents were US$59.5 million, with estimated funding capacity of 6.9 quarters. Capital expenditures totaled 2,260 $USD’000, mainly for the Riverside facility, and related-party payments were US$281,000. The company has fully drawn US$40,000,000 in unsecured convertible debentures and a USD$30,100,000 real estate facility.
NOVONIX Ltd director Sharan Burrow reported acquiring 31,250 ordinary shares on 2026-07-22 in an "other" acquisition (transaction code J) at $0.16 per share. Following this transaction, Burrow directly holds 246,989 ordinary shares. The Rule 10b5-1 trading-plan checkbox is not marked.
Novonix Limited, a foreign private issuer, reported an update to director Sharan Burrow’s holdings. An issue of shares under the company’s Share Purchase Plan changed her direct relevant interest, and she now holds 246,989 ordinary shares and 195,938 share rights. No changes were reported to any related contracts, and it was confirmed that the interests were not traded during a closed period requiring prior written clearance.
NOVONIX Limited completed a Share Purchase Plan, issuing 6,016,250 fully paid ordinary shares at A$0.16 each to raise A$962,600 before costs. The offer, which closed on 17 July 2026, allowed eligible shareholders to apply for up to A$30,000 of new shares.
The company plans to use the proceeds to fund capital expenditure to support production capacity and forecast customer demand. Valid applications were received from approximately 89 eligible shareholders, with an average application of approximately A$10,816 and a participation rate of approximately 0.3% of eligible shareholders.
The 6,016,250 new SPP Shares represent approximately 0.6% of NOVONIX’s ordinary shares on issue. Following quotation, total ordinary fully paid shares quoted on ASX are 997,612,994.
NOVONIX Limited updated the timetable for its previously announced Share Purchase Plan (SPP). The SPP will now close at 5:00pm AEST on 17 July 2026, brought forward from the earlier closing date. Applications and payments must be received in cleared funds by that time, otherwise they will be rejected and application monies returned in full without interest.
The company targets announcing SPP results on or about 20 July 2026, with allotment of SPP shares on or about 22 July 2026 and trading expected to commence on or about 23 July 2026, subject to ASX confirmation and applicable rules.
NOVONIX Limited reports that the ASX has granted waivers from Listing Rules 7.1 and 10.11 for its Share Purchase Plan. These waivers allow NOVONIX to issue new SPP shares at an offer price of $0.16 per share without prior shareholder approval and without using its standard placement capacity.
The offer price is the same as the institutional placement completed earlier and represents a discount of about 31.2% to the 5-day VWAP calculated to 15 June 2026. The company expects overall dilution from the SPP to be approximately 2.17%, with SPP shares capped at no more than 30% of existing fully paid ordinary shares.
The SPP timetable runs from a record date on 16 June 2026, opens on 22 June 2026, closes on 14 August 2026, with allotment on or about 19 August 2026 and trading of SPP shares expected to commence on or about 20 August 2026.
NOVONIX LIMITED has applied to quote 34,824 additional ordinary fully paid shares on the ASX, issued on July 3, 2026 after performance rights were converted under an employee incentive scheme. These new shares are valued at an estimated AUD 0.155 per security and rank equally with existing shares.
Following this small non-cash issuance, the company’s total quoted ordinary share capital will comprise 991,596,744 NVX ordinary fully paid shares. NOVONIX also has several classes of unquoted securities on issue, including performance rights, options, share rights, convertible notes and convertible debentures.
NOVONIX Ltd Chief Financial Officer Robert Buell Long reported internal changes to his equity awards involving performance rights. On June 30, 2026, three transactions coded as “J” (Other acquisition or disposition) affected a total of 4,576,670 performance rights tied to ordinary shares, all at a reported price of $0.00 per right. Each line shows zero performance rights remaining of that series following the transactions, and no ordinary share purchases or sales were reported.
NOVONIX Limited has detailed the pay package for Ron Edmonds as Interim Chief Financial Officer. His interim term runs for 3–6 months from 1 July 2026.
Mr Edmonds will receive a USD$450,000 base salary, pro‑rated for an expected 75% workload, plus a short‑term incentive of up to 100% of fixed pay based on Board‑set performance targets. He is also eligible for additional Director share rights valued at USD$95,000, subject to shareholder approval.
He remains a director but has stepped aside as Chair while serving as Interim CFO. Deputy Chair Admiral Robert Natter has resumed the role of Chair for the interim period, and the arrangements will continue until a permanent CFO is appointed or his interim role ends earlier.
NOVONIX Limited reported a change to its share capital after certain employee-style awards lapsed. On 30 June 2026, a total of 5,781,507 NVXAD PERFORMANCE RIGHTS ceased due to the lapse of conditional rights where vesting conditions were not, or could not be, satisfied. The company confirmed it paid no consideration for this cessation.
After this change, NOVONIX’s issued capital includes 991,561,920 NVX ordinary fully paid shares on issue and unquoted equity securities such as 21,619,875 NVXAD performance rights, 14,016,667 NVXAA options, 1,371,566 NVXAB share rights and 45,221,586 NVXAL convertible notes.